Author: Li Hui Li Xiangping Liu Qingyou Shi Zhendan Shi Deshun
Publisher: Humana Press, Inc
ISSN: 0273-2289
Source: Applied Biochemistry and Biotechnology, Vol.171, Iss.6, 2013-11, pp. : 1535-1544
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Human interferon alpha 2b (IFNα-2b) is a pleiotropic cytokine used to treat various viral diseases and cancers. Conventionally, recombinant human IFNα-2b used in clinics was produced by prokaryotic expression system, which always lack of enough biological activity due to limitations on proper folding and post-translational modifications, so the eukaryotic expression system are becoming prevailing method for the production of recombinant proteins. In this study, human breast cancer cell Bcap-37 was firstly used as host for the expression of human IFNα-2b, with the expression vector pIRES2-IFN-EGFP, in which IFNα-2b gene is under the control of CMV promoter. The expression of recombinant IFNα-2b was detected by Western blot and ELISA. Results showed that the concentration of the secreted recombinant IFNα-2b in culture medium was 435.7 pg/mL/24 h. Biological activity of the recombinant IFNα-2b was assayed by detecting the expression of IFN-inducible genes, including MxA, OAS, PKR, and Caspase1 through QRT-PCR. Results demonstrated that recombinant IFNα-2b possess the biological activities. Compared to non-transgenic cells, the expression levels of the aforementioned four IFN-inducible genes were increased by 18.098-, 1.843-, 2.21-, and 3.066-folds, respectively. We got to a conclusion that the human breast cancer cell Bcap-37 could express bioactive recombinant IFNα-2b.
Related content
By Li Y. Wood N. Yellowlees D. Donnelly P.
Biochemical and Biophysical Research Communications, Vol. 240, Iss. 1, 1997-11 ,pp. :
By Das T. Johns P.W. Goffin V. Kelly P. Kelder B. Kopchick J. Buxton K. Mukerji P.
Protein Expression and Purification, Vol. 20, Iss. 2, 2000-11 ,pp. :